clonidine has been researched along with Tachycardia in 43 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Tachycardia: Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied the pressor and tachycardiac responses to ephedrine in elderly and young patients given either clonidine or midazolam during propofol anesthesia." | 9.10 | The effects of clonidine premedication on the blood pressure and tachycardiac responses to ephedrine in elderly and young patients during propofol anesthesia. ( Ishiyama, T; Kashimoto, S; Kumazawa, T; Matsukawa, T; Oguchi, T, 2003) |
| "A rapid increase in isoflurane concentration can induce tachycardia and hypertension and increase plasma catecholamine concentrations." | 9.07 | Clonidine and lidocaine inhibition of isoflurane-induced tachycardia in humans. ( Namba, H; Namiki, A; Tanaka, S; Tsuchida, H, 1994) |
| "Experiments were performed in a randomized double-blind cross-over study in 6 healthy volunteers to answer the question if alinidine, a new analogue of clonidine with a bradycardic effect directly on the sinus node, would have an effect on an emotionally-induced tachycardia." | 9.05 | The effect of alinidine (St 567) on emotionally induced tachycardia in man. ( Auböck, J; Konzett, H; Olbrich, E, 1982) |
| " To test this hypothesis, the effects of 2 clinically available α-2 AR agonists (dexmedetomidine and clonidine) on the occurrence of VTs were assessed in a methoxamine-sensitized rabbit model of acquired long QT syndrome (Study 1: n=45)." | 7.78 | Dexmedetomidine and clonidine inhibit ventricular tachyarrhythmias in a rabbit model of acquired long QT syndrome. ( Ajiki, K; Hayami, N; Kanamori, K; Kunishima, T; Mikamo, T; Murakawa, Y; Sugiura, A; Tsutsui, K; Watanabe, H; Yamagishi, N; Yamagishi, S, 2012) |
| "), on ventricular tachycardia (VT) induced by intravenous acetylstrophanthidin (AS) were studied in cats anaesthetized with intraperitoneal chloralose." | 7.68 | Termination of digitalis-induced ventricular tachycardias by clonidine involves central alpha 2-adrenoceptors in cats. ( Chang, MS; Chen, SA; Chiang, BN; Kuo, JS; Liu, RH; Ting, TH, 1991) |
| "05 mg/kg, IA), on the ventricular tachycardia (VT) induced with IV acetyl strophanthidin (AS) were studied in cats anesthetized with intraperitoneal chloralose." | 7.68 | Clonidine suppresses digitalis-induced ventricular tachycardia in cats. ( Chang, MS; Chen, SA; Chiang, BN; Kuo, JS; Liu, RH; Ting, TH, 1990) |
| "Withdrawal of chronic infusion of clonidine elicits severe tachycardia and short-lasting blood pressure elevations (upswings)." | 7.67 | Location of the mechanism of the clonidine withdrawal tachycardia in rats. ( Jonkman, FA; Man, PW; Thoolen, MJ; van Zwieten, PA, 1985) |
| "Ventricular tachycardia developed after the abrupt withdrawal of clonidine in a patient with atrial septal defect of the ostium secundum type, renal insufficiency, and hypertension." | 7.67 | Ventricular tachycardia induced by clonidine withdrawal. ( Koiwaya, Y; Nakagawa, S; Yamamoto, Y, 1985) |
| "His palpitations and presyncope were reproducible on deep inspiration, coughing, isometric hand exercise and passive leg raises." | 5.46 | Respiration driven excessive sinus tachycardia treated with clonidine. ( Hayat, S; Li Kam Wa, ME; Lim, PB; Taraborrelli, P, 2017) |
| "There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17." | 5.13 | Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. ( Bukstein, OG; Daviss, WB; Harris, P; McDERMOTT, MP; Palumbo, D; Patel, NC; Pelham, WE; Robb, AS; Sallee, FR, 2008) |
| "We studied the pressor and tachycardiac responses to ephedrine in elderly and young patients given either clonidine or midazolam during propofol anesthesia." | 5.10 | The effects of clonidine premedication on the blood pressure and tachycardiac responses to ephedrine in elderly and young patients during propofol anesthesia. ( Ishiyama, T; Kashimoto, S; Kumazawa, T; Matsukawa, T; Oguchi, T, 2003) |
| "A rapid increase in isoflurane concentration can induce tachycardia and hypertension and increase plasma catecholamine concentrations." | 5.07 | Clonidine and lidocaine inhibition of isoflurane-induced tachycardia in humans. ( Namba, H; Namiki, A; Tanaka, S; Tsuchida, H, 1994) |
| "Experiments were performed in a randomized double-blind cross-over study in 6 healthy volunteers to answer the question if alinidine, a new analogue of clonidine with a bradycardic effect directly on the sinus node, would have an effect on an emotionally-induced tachycardia." | 5.05 | The effect of alinidine (St 567) on emotionally induced tachycardia in man. ( Auböck, J; Konzett, H; Olbrich, E, 1982) |
| " Our review, based on moderate-quality evidence, revealed that hypotension occurred frequently during the preoperative and postoperative periods, for both clonidine and dexmedetomidine." | 5.01 | Perioperative adverse events attributed to α2-adrenoceptor agonists in patients not at risk of cardiovascular events: systematic review and meta-analysis. ( Antunes, T; Demiri, M; Fletcher, D; Martinez, V, 2019) |
| " Presently, the most robust clinical evidence involves the use of the cardioselective β-blocker esmolol in patients with septic shock with persistent tachycardia secondary to catecholamine use." | 4.98 | Misdirected Sympathy: The Role of Sympatholysis in Sepsis and Septic Shock. ( Bissell, BD; Ferreira, JA, 2018) |
| " To test this hypothesis, the effects of 2 clinically available α-2 AR agonists (dexmedetomidine and clonidine) on the occurrence of VTs were assessed in a methoxamine-sensitized rabbit model of acquired long QT syndrome (Study 1: n=45)." | 3.78 | Dexmedetomidine and clonidine inhibit ventricular tachyarrhythmias in a rabbit model of acquired long QT syndrome. ( Ajiki, K; Hayami, N; Kanamori, K; Kunishima, T; Mikamo, T; Murakawa, Y; Sugiura, A; Tsutsui, K; Watanabe, H; Yamagishi, N; Yamagishi, S, 2012) |
| " In this report, we describe a 15-year-old adolescent girl who experienced continued delirium 5 days after an overdose of quetiapine, trazodone, and clonidine." | 3.76 | Prolonged delirium after quetiapine overdose. ( Pedapati, EV; Rhyee, SH; Thompson, J, 2010) |
| " The presence of alpha 1-adrenergic receptors at this site was confirmed by microinjections of phenylephrine (a specific agonist for these receptors); phenylephrine elicited tachycardia." | 3.68 | Cardiac effects of injections of epinephrine into the spinal intermediolateral column. ( Kachroo, A; Malhotra, VK; Sapru, HN, 1993) |
| " All the patients had excessive pressor and tachycardia responses to the mental-arithmetic and cold pressor tests and marked hypersensitivity to clonidine." | 3.68 | The diagnosis and treatment of baroreflex failure. ( Biaggioni, I; Hollister, AS; Mosqueda-Garcia, R; Netterville, JL; Robertson, D; Robertson, RM, 1993) |
| "), on ventricular tachycardia (VT) induced by intravenous acetylstrophanthidin (AS) were studied in cats anaesthetized with intraperitoneal chloralose." | 3.68 | Termination of digitalis-induced ventricular tachycardias by clonidine involves central alpha 2-adrenoceptors in cats. ( Chang, MS; Chen, SA; Chiang, BN; Kuo, JS; Liu, RH; Ting, TH, 1991) |
| "05 mg/kg, IA), on the ventricular tachycardia (VT) induced with IV acetyl strophanthidin (AS) were studied in cats anesthetized with intraperitoneal chloralose." | 3.68 | Clonidine suppresses digitalis-induced ventricular tachycardia in cats. ( Chang, MS; Chen, SA; Chiang, BN; Kuo, JS; Liu, RH; Ting, TH, 1990) |
| "Withdrawal of chronic infusion of clonidine elicits severe tachycardia and short-lasting blood pressure elevations (upswings)." | 3.67 | Location of the mechanism of the clonidine withdrawal tachycardia in rats. ( Jonkman, FA; Man, PW; Thoolen, MJ; van Zwieten, PA, 1985) |
| "Ventricular tachycardia developed after the abrupt withdrawal of clonidine in a patient with atrial septal defect of the ostium secundum type, renal insufficiency, and hypertension." | 3.67 | Ventricular tachycardia induced by clonidine withdrawal. ( Koiwaya, Y; Nakagawa, S; Yamamoto, Y, 1985) |
| " In intact anesthetized, vagotomized rats or in pithed rats with a submaximal tachycardia evoked by electrical stimulation of the spinal cord, clonidine and oxymetazoline, in contrast to cirazoline (5." | 3.66 | Functional and biochemical evidence for the lack of cardiac presynaptic alpha-2 adrenoceptor stimulant properties of cirazoline (LD 3098), a potent alpha-1 adrenoceptor agonist in dogs and rats. ( Cavero, I; Gomeni, R; Lefèvre-Borg, F; Roach, AG; Scatton, B, 1982) |
| "Clonidine was associated with a significant (P < 0." | 2.69 | Clonidine and cardiac surgery: haemodynamic and metabolic effects, myocardial ischaemia and recovery. ( Buckland, MR; Bujor, MA; Davis, BB; Esmore, DS; Hall, J; Holdgaard, HO; Hunt, JO; McRae, R; Moloney, J; Morgan, DJ; Myles, PS, 1999) |
| "Sevoflurane was titrated against a BIS held between 40 and 50." | 2.69 | Influence of intravenous clonidine pretreatment on anesthetic requirements during bispectral EEG-guided sevoflurane anesthesia. ( Buyse, L; De Deyne, C; De Jongh, R; Deghislage, J; Heylen, R; Rolly, G; Struys, M; Van der Laenen, M, 2000) |
| "His palpitations and presyncope were reproducible on deep inspiration, coughing, isometric hand exercise and passive leg raises." | 1.46 | Respiration driven excessive sinus tachycardia treated with clonidine. ( Hayat, S; Li Kam Wa, ME; Lim, PB; Taraborrelli, P, 2017) |
| "Isoflurane caused an increase in HR at 0." | 1.29 | Effects of isoflurane on cardiovascular system and sympathovagal balance in New Zealand white rabbits. ( Grigioni, M; Marano, G; Tiburzi, F; Vergari, A; Zanghi, F, 1996) |
| "dose, a tachycardia was observed in all rats following initial transient bradycardia." | 1.27 | Tachycardic and hypertensive effects of centrally administered clonidine in conscious rats. ( Imai, Y; Johnston, CI; Nolan, PL, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (41.86) | 18.7374 |
| 1990's | 13 (30.23) | 18.2507 |
| 2000's | 7 (16.28) | 29.6817 |
| 2010's | 5 (11.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Demiri, M | 1 |
| Antunes, T | 1 |
| Fletcher, D | 1 |
| Martinez, V | 1 |
| Li Kam Wa, ME | 1 |
| Taraborrelli, P | 1 |
| Hayat, S | 1 |
| Lim, PB | 1 |
| Ferreira, JA | 1 |
| Bissell, BD | 1 |
| Liatsi, D | 1 |
| Tsapas, B | 1 |
| Pampori, S | 1 |
| Tsagourias, M | 1 |
| Pneumatikos, I | 1 |
| Matamis, D | 1 |
| Rhyee, SH | 1 |
| Pedapati, EV | 1 |
| Thompson, J | 1 |
| Tsutsui, K | 1 |
| Hayami, N | 1 |
| Kunishima, T | 1 |
| Sugiura, A | 1 |
| Mikamo, T | 1 |
| Kanamori, K | 1 |
| Yamagishi, N | 1 |
| Yamagishi, S | 1 |
| Watanabe, H | 1 |
| Ajiki, K | 1 |
| Murakawa, Y | 1 |
| Ishiyama, T | 1 |
| Kashimoto, S | 1 |
| Oguchi, T | 1 |
| Matsukawa, T | 1 |
| Kumazawa, T | 1 |
| Skinner, AV | 1 |
| Chalkiadis, GA | 1 |
| Daviss, WB | 1 |
| Patel, NC | 1 |
| Robb, AS | 1 |
| McDERMOTT, MP | 1 |
| Bukstein, OG | 1 |
| Pelham, WE | 1 |
| Palumbo, D | 1 |
| Harris, P | 1 |
| Sallee, FR | 1 |
| Uchida, W | 1 |
| Kimura, T | 1 |
| Satoh, S | 1 |
| Thoolen, MJ | 2 |
| Timmermans, PB | 1 |
| Van Zwieten, PA | 2 |
| Cavero, I | 1 |
| Lefèvre-Borg, F | 1 |
| Roach, AG | 1 |
| Gomeni, R | 1 |
| Scatton, B | 1 |
| Boyer, JL | 1 |
| Cárdenas, C | 1 |
| Posadas, C | 1 |
| García-Sáinz, JA | 1 |
| Stiff, JL | 1 |
| Harris, DB | 1 |
| Auböck, J | 1 |
| Konzett, H | 1 |
| Olbrich, E | 1 |
| Tanaka, S | 1 |
| Tsuchida, H | 1 |
| Namba, H | 1 |
| Namiki, A | 1 |
| Malhotra, VK | 1 |
| Kachroo, A | 1 |
| Sapru, HN | 1 |
| Robertson, D | 3 |
| Hollister, AS | 1 |
| Biaggioni, I | 2 |
| Netterville, JL | 1 |
| Mosqueda-Garcia, R | 2 |
| Robertson, RM | 2 |
| Munro, HM | 1 |
| Sleigh, JW | 1 |
| Paxton, LD | 1 |
| Marano, G | 1 |
| Grigioni, M | 1 |
| Tiburzi, F | 1 |
| Vergari, A | 1 |
| Zanghi, F | 1 |
| Nishikawa, T | 1 |
| Jacob, G | 1 |
| Shannon, JR | 1 |
| Black, B | 1 |
| Myles, PS | 1 |
| Hunt, JO | 1 |
| Holdgaard, HO | 1 |
| McRae, R | 1 |
| Buckland, MR | 1 |
| Moloney, J | 1 |
| Hall, J | 1 |
| Bujor, MA | 1 |
| Esmore, DS | 1 |
| Davis, BB | 1 |
| Morgan, DJ | 1 |
| Fujii, Y | 1 |
| Saitoh, Y | 1 |
| Tanaka, H | 1 |
| Toyooka, H | 1 |
| Gordon, VM | 1 |
| Opfer-Gehrking, TL | 1 |
| Novak, V | 1 |
| Low, PA | 1 |
| De Deyne, C | 1 |
| Struys, M | 1 |
| Heylen, R | 1 |
| De Jongh, R | 1 |
| Van der Laenen, M | 1 |
| Buyse, L | 1 |
| Deghislage, J | 1 |
| Rolly, G | 1 |
| Spach, MO | 1 |
| Steimer, C | 1 |
| Bloch, R | 1 |
| Metz, SA | 1 |
| Halter, JB | 1 |
| Porte, D | 1 |
| Robertson, RP | 1 |
| Chen, SA | 2 |
| Liu, RH | 2 |
| Ting, TH | 2 |
| Chang, MS | 2 |
| Chiang, BN | 2 |
| Kuo, JS | 2 |
| Jain, P | 1 |
| Misra, A | 1 |
| Bernard, JM | 1 |
| Quintin, L | 2 |
| Pinaud, M | 1 |
| Jonkman, FA | 1 |
| Man, PW | 1 |
| Harron, DW | 1 |
| Shanks, RG | 1 |
| Dabire, H | 1 |
| Dausse, JP | 1 |
| Mouille, P | 1 |
| Fournier, B | 1 |
| Cardot, A | 1 |
| Meyer, P | 1 |
| Schmitt, H | 1 |
| Ghignone, M | 1 |
| Nakagawa, S | 2 |
| Yamamoto, Y | 2 |
| Koiwaya, Y | 2 |
| Longnecker, DE | 1 |
| Imai, Y | 1 |
| Nolan, PL | 1 |
| Johnston, CI | 1 |
| Lagrue, G | 1 |
| Weil, B | 1 |
| Buisson, C | 1 |
| Gillis, RA | 1 |
| Dionne, RA | 1 |
| Standaert, FG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study to Quantify the Autonomic Nervous System Balance in Healthy, Able-Bodied Individuals[NCT04100486] | 48 participants (Anticipated) | Observational | 2019-08-29 | Enrolling by invitation | |||
| Effect of Clonidine vs. Dexmedetomidine in Addition to Standard Treatment in Agitated Delirium in Intensive Care Patients: Pilot Study.[NCT04758936] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | ||
| A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist[NCT03070730] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2011-08-15 | Terminated (stopped due to Recruitment was slow and subjects declined participation after signing the ICF.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: up to 3 days after randomization
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: Up to 3 days after randomization
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
6 reviews available for clonidine and Tachycardia
| Article | Year |
|---|---|
Perioperative adverse events attributed to α2-adrenoceptor agonists in patients not at risk of cardiovascular events: systematic review and meta-analysis.
Topics: Adrenergic alpha-2 Receptor Agonists; Bradycardia; Clonidine; Dexmedetomidine; Humans; Hypotension; | 2019 |
Misdirected Sympathy: The Role of Sympatholysis in Sepsis and Septic Shock.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-1 Receptor Antagonists; Animals; Catecholamine | 2018 |
[Preoperative evaluation of patients with heart dysfunction and preanesthetic medication].
Topics: Adrenergic alpha-Agonists; Anesthesia, General; Clonidine; Coronary Disease; Heart Failure; Heart Fu | 1996 |
Diagnosis and management of baroreflex failure.
Topics: Antihypertensive Agents; Autonomic Nervous System Diseases; Baroreflex; Bradycardia; Carotid Sinus; | 1995 |
[Clonidine: from the treatment of hypertension to its use in anesthesia. II: Perioperative use].
Topics: Analgesia; Anesthesia; Anesthetics; Animals; Clonidine; Hemodynamics; Humans; Hypertension; Hypotens | 1990 |
Pharmacology, clinical pharmacology and potential therapeutic uses of the specific bradycardiac agent alinidine.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Clonidine; Coronary Disease; Drug Evaluation; | 1985 |
10 trials available for clonidine and Tachycardia
| Article | Year |
|---|---|
The effects of clonidine premedication on the blood pressure and tachycardiac responses to ephedrine in elderly and young patients during propofol anesthesia.
Topics: Adjuvants, Anesthesia; Adrenergic alpha-Agonists; Adult; Aged; Aging; Anesthesia, Intravenous; Anest | 2003 |
Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis.
Topics: Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Bradycardia; Central Nervo | 2008 |
The effect of alinidine (St 567) on emotionally induced tachycardia in man.
Topics: Adult; Blood Pressure; Clonidine; Drug Evaluation; Heart Rate; Humans; Male; Stress, Psychological; | 1982 |
Clonidine and lidocaine inhibition of isoflurane-induced tachycardia in humans.
Topics: Administration, Topical; Adult; Anesthesia, Inhalation; Clonidine; Dose-Response Relationship, Drug; | 1994 |
The cardiovascular response to ketamine: the effects of clonidine and lignocaine.
Topics: Adult; Aged; Clonidine; Double-Blind Method; Female; Humans; Hypertension; Ketamine; Lidocaine; Male | 1993 |
Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Blood Pressure; Blood Volume; Clonidine; Female; Heart | 1997 |
Clonidine and cardiac surgery: haemodynamic and metabolic effects, myocardial ischaemia and recovery.
Topics: Adrenergic alpha-Agonists; Aged; Anesthetics, Intravenous; Clonidine; Coronary Artery Bypass; Creati | 1999 |
Pretreatment with oral clonidine attenuates cardiovascular responses to tracheal extubation in children.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Anesthesia, General; Antiemetics; Antihypertensive | 2000 |
Influence of intravenous clonidine pretreatment on anesthetic requirements during bispectral EEG-guided sevoflurane anesthesia.
Topics: Adolescent; Adult; Aged; Anesthesia, Inhalation; Anesthetics, Inhalation; Anesthetics, Local; Bupiva | 2000 |
[Clonidine: from the treatment of hypertension to its use in anesthesia. II: Perioperative use].
Topics: Analgesia; Anesthesia; Anesthetics; Animals; Clonidine; Hemodynamics; Humans; Hypertension; Hypotens | 1990 |
28 other studies available for clonidine and Tachycardia
| Article | Year |
|---|---|
Respiration driven excessive sinus tachycardia treated with clonidine.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Benzazepines; Cardiovascular Agents; Clonidine; Cough; | 2017 |
Respiratory, metabolic and hemodynamic effects of clonidine in ventilated patients presenting with withdrawal syndrome.
Topics: Adrenergic alpha-Agonists; Adult; Calorimetry, Indirect; Carbon Dioxide; Clonidine; Electrocardiogra | 2009 |
Prolonged delirium after quetiapine overdose.
Topics: Adolescent; Antipsychotic Agents; Cholinergic Antagonists; Clonidine; Cytochrome P-450 CYP3A; Deliri | 2010 |
Dexmedetomidine and clonidine inhibit ventricular tachyarrhythmias in a rabbit model of acquired long QT syndrome.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Animals; Anti-Arrhythmia | 2012 |
Clinically unrecognized intravascular placement of epidural catheter in a child--an argument for the use of radio-opaque contrast?
Topics: Adrenergic Agonists; Analgesia, Epidural; Analgesics; Anesthetics, Local; Blood Pressure; Bupivacain | 2007 |
Presence of presynaptic inhibitory alpha 1-adrenoceptors in the cardiac sympathetic nerves of the dog: effects of prazosin and yohimbine on sympathetic neurotransmission to the heart.
Topics: Animals; Clonidine; Dogs; Female; Heart Rate; Male; Methoxamine; Myocardium; Norepinephrine; Prazosi | 1984 |
Withdrawal syndrome after continuous infusion of clonidine in the normotensive rat.
Topics: Animals; Blood Pressure; Clonidine; Heart Rate; Humans; Male; Norepinephrine; Rats; Rats, Inbred Str | 1981 |
Functional and biochemical evidence for the lack of cardiac presynaptic alpha-2 adrenoceptor stimulant properties of cirazoline (LD 3098), a potent alpha-1 adrenoceptor agonist in dogs and rats.
Topics: Adrenergic alpha-Agonists; Animals; Blood Pressure; Blood Vessels; Brimonidine Tartrate; Clonidine; | 1982 |
"Pertussis toxin induces tachycardia and impairs the increase in blood pressure produced by alpha 2-adrenergic agonists".
Topics: Animals; Azepines; Bacterial Toxins; Blood Pressure; Bordetella pertussis; Clonidine; Dose-Response | 1983 |
Clonidine withdrawal complicated by amitriptyline therapy.
Topics: Aged; Amitriptyline; Anxiety; Clonidine; Female; Humans; Hypertension; Intraoperative Care; Methyldo | 1983 |
Cardiac effects of injections of epinephrine into the spinal intermediolateral column.
Topics: Animals; Bradycardia; Clonidine; Dose-Response Relationship, Drug; Epinephrine; Heart; Heart Rate; I | 1993 |
The diagnosis and treatment of baroreflex failure.
Topics: Adult; Baroreflex; Blood Pressure; Catecholamines; Clonidine; Female; Humans; Hypertension; Male; Mi | 1993 |
Effects of isoflurane on cardiovascular system and sympathovagal balance in New Zealand white rabbits.
Topics: Anesthetics, Inhalation; Animals; Atenolol; Baroreflex; Blood Pressure; Cardiovascular Physiological | 1996 |
Hemodynamic and symptomatic effects of acute interventions on tilt in patients with postural tachycardia syndrome.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Antihypertensive Agents; Clonidine; Female; Hemodynamics; | 2000 |
[Clinical and biological manifestations following the interruption of prolonged treatment with clonidine].
Topics: Adult; Aged; Blood Pressure; Clonidine; Dose-Response Relationship, Drug; Epinephrine; Female; Heart | 1977 |
Autonomic epilepsy: clonidine blockade of paroxysmal catecholamine release and flushing.
Topics: Autonomic Nervous System; Carbamazepine; Catecholamines; Climacteric; Clonidine; Epilepsy; Epilepsy, | 1978 |
Termination of digitalis-induced ventricular tachycardias by clonidine involves central alpha 2-adrenoceptors in cats.
Topics: Animals; Anti-Arrhythmia Agents; Blood Pressure; Cats; Clonidine; Digitalis Glycosides; Dose-Respons | 1991 |
Non-sustained ventricular tachycardia following clonidine withdrawal.
Topics: Clonidine; Heart Ventricles; Humans; Male; Middle Aged; Substance Withdrawal Syndrome; Tachycardia | 1991 |
Clonidine suppresses digitalis-induced ventricular tachycardia in cats.
Topics: Animals; Anti-Arrhythmia Agents; Cats; Clonidine; Digitalis; Female; Heart Ventricles; Male; Plants, | 1990 |
Location of the mechanism of the clonidine withdrawal tachycardia in rats.
Topics: Animals; Blood Pressure; Clonidine; Injections, Intraventricular; Injections, Subcutaneous; Male; Ox | 1985 |
Pharmacological properties of the enantiomers of idazoxan: possible separation between their alpha-adrenoceptor blocking effects.
Topics: Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Blood Pressure; Cerebral Cortex; Chicke | 1986 |
[Preoperative oral clonidine improves the cardiovascular stability of hypertensive and coronary patients undergoing surgery].
Topics: Administration, Oral; Cardiovascular System; Clonidine; Coronary Disease; Humans; Hypertension; Prem | 1987 |
Alpha receptors and ventricular tachycardia after clonidine withdrawal.
Topics: Clonidine; Humans; Receptors, Adrenergic, alpha; Substance Withdrawal Syndrome; Tachycardia | 1986 |
Alpine anesthesia: can pretreatment with clonidine decrease the peaks and valleys?
Topics: Anesthesia, General; Clonidine; Humans; Hypertension; Preanesthetic Medication; Tachycardia | 1987 |
Tachycardic and hypertensive effects of centrally administered clonidine in conscious rats.
Topics: Animals; Atropine; Blood Pressure; Bradycardia; Clonidine; Heart Rate; Hypertension; Hypotension; In | 1986 |
Ventricular tachycardia induced by clonidine withdrawal.
Topics: Blood Pressure; Clonidine; Electrocardiography; Female; Humans; Middle Aged; Phentolamine; Prazosin; | 1985 |
[General principles of antihypertensive treatment].
Topics: Antihypertensive Agents; Cardiac Output; Clonidine; Follow-Up Studies; Ganglionic Blockers; Guanethi | 1974 |
Suppression by clonidine (St-155) of cardiac arrhythmias induced by digitalis.
Topics: Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Cats; Clonidine; Depression, | 1972 |